MedGenesis Therapeutix Inc. MedGenesis Therapeutix Inc.


News ] [ Our People ] [ Awards ]

Our People

[Management Team ] [ Scientific Advisors ] [ Board of Directors ]

Board of Directors

ErichErich Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.

Erich Mohr, Ph.D., R.Psych, is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2005. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 20 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, books, book chapters and abstracts and has edited the Handbook of Clinical Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc. (which merged with PRA International in 2002 to form one of the top 5 contract research organizations in the world) and the co-founder of several biotechnology companies. His most recent position was with PRA International, where he served as Chief Scientific Officer. Over the course of his career, Dr. Mohr has overseen and/or participated in dozens of clinical development programs resulting in a number of approved drugs.

PatPatrick (Pat) K. Donnelly
Current Chairman & Chief Executive Officer, Aptiv Solutions
Former President & Chief Executive Officer, PRA International

Mr. Donnelly is the former President & CEO, and Board Member of PRA International (NASDAQ: PRAI). Having joined the company in 1994, he was instrumental in directing PRA's dramatic growth from a small regional contract research organization to one of the top global players in the industry with over $335 million in revenue. During his tenure as Chief Financial Officer and Chief Operating Officer, then as President, and in 2002 as CEO, he executed and integrated thirteen strategic international acquisitions as well as lead the company through its IPO in 2004, and subsequent successful secondary offering in 2005 both raising over $275 million and stock appreciation of 50% since the IPO. In 2006, PRA International was named to Forbes' Top 200 Best Small Companies and in 2005 it was ranked 55th in BusinessWeek's Top 100 Growth Companies. Prior to his tenure at PRA, he was President of Virginia Capital, L.P. and Vedcorp, LLC, two affiliated venture capital firms. He also spent eight years with BancBoston Capital. Mr. Donnelly graduated from The Pennsylvania State University with a MBA in 1984 and a BS from the University of Missouri in 1980.

ChrisH. Christian Fibiger, Ph.D.
Chief Scientific Officer

H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from Princeton University in 1970. Dr. Fibiger was formerly the Chief Scientific Officer for Biovail Laboratories International (now Valeant). From 2003 until 2007 he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen’s worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver. He has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Fibiger serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology.

KenKen Newport
Former President, CroMedica Global Inc.

Ken Newport is an entrepreneur and life sciences business executive. As a graduate from the University of Waterloo and a Chartered Accountant, Mr. Newport had early success in the financial services industry and served as a partner in a Chartered Accounting firm. His focus changed to life sciences in the mid nineties with the formation of CroMedica Global Inc., a contract research organization. As co-founder and President he witnessed CroMedica's growth to 600 employees within six years. By the time that CroMedica merged with PRA International Inc. in 2002 CroMedica had annual revenues of over $40 million with 13 offices in 9 countries. The combined company became one of the 5 largest contract research organizations in the world with 2,600 employees. Mr. Newport served as a Senior Vice President and Executive Committee member for the last three years until his recent retirement. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is now a corporate director on several corporate and not for profit Boards including his role as Chairman of BioCanRx.



© MedGenesis Therapeutix Inc.